Figure Legends:
Figure 1: FDA approved compounds and compounds in clinical trial targeting GPCRs. (A) 106 (31.64%) de-orphaned GPCRs currently have an FDA approved compound to target them, compared to only 1 (1.14%) oGPCR (left). Further, there are currently 57 (17.01%) de-orphaned GPCRs that have a drug in ongoing clinical trials, compared to only 2 (2.27%) drugs targeting oGPCR (right). (B) Of the total number of FDA approved drugs targeting de-orphaned GPCRs, 130 (27.08%) are for CNS indications, whilst there are no approved drugs targeting oGPCRs for CNS indications. Further, 27 (35.53%) of the de-orphaned GPCRs currently being targeted in ongoing clinical trials are for CNS indications, whilst no oGPCRs are currently being targeted in ongoing clinical trials for CNS indications.
Figure 2: Orphan neuropeptide and receptor expression in key brain regions implicated in alcohol use disorder, colour-coded according to the three key phases of the addiction cycle (binge/intoxication, withdrawal/negative affect, preoccupation/anticipation). Amyg., amygdala; CART, cocaine- and amphetamine-regulated transcript; Hab., habenula; Hipp., hippocampus; Hypo., hypothalamus; PFC, prefrontal cortex; VTA, ventral tegmental area.